Last updated on May 2020

Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy


Brief description of study

This is an single arm, open label, interventional phase II trial evaluating the efficacy of umbilical cord blood (UCB) hematopoietic stem and progenitor cells (HSPC) expanded in culture with stimulatory cytokines (SCF, Flt-3L, IL-6 and thromopoietin) on lympho-hematopoietic recovery. Patients will receive a uniform myeloablative conditioning and post-transplant immunoprophylaxis.

Clinical Study Identifier: NCT03674411

Find a site near you

Start Over